The Magazine for Sleep Professionals
Friday, August 28, 2026
There has been an increasing number of studies looking at orofacial myofunctional therapy (OMT) as a promising adjunctive treatment for obstructive sleep apnea (OSA).1 OMT essentially helps the patient to retrain the muscles around the face, mouth, and tongue to establish correct oral rest posture and functioning of the oral […]
ProSomnus Sleep Technologies announced record revenues for the quarter that ended June 30, 2024, as it formally emerged from reorganization on August 5, 2024. Revenues for the second quarter totaled a record $9.1 million reflecting increasing orders for the Company’s precision intraoral medical devices. These quarterly results reflect a 22% […]
Panthera Dental is pleased to announce a remarkable milestone in its ongoing commitment to innovation and excellence: the company now holds over 110 patents across the dental, medical, and sleep appliance industries. This significant milestone follows their recent amicable settlement with ResMed SAS that resolves all ongoing patent infringement litigation […]
ProSomnus, Inc. announced it has initiated a voluntary restructuring process under Chapter 11 of the U.S. Bankruptcy Code to reorganize and strengthen its capital structure going forward, improve financial flexibility and better position the company for long-term success. In connection with this process, the Company has secured the support of […]
Panthera Dental proudly announces that two distinct abstracts were accepted for poster presentations at the AADSM and AASM/SLEEP Annual Meetings. In addition, a funding opportunity through Panthera for investigator-initiated research proposals will be announced. The posters and the “Panthera Sleep Research Grant” reflect Panthera’s dedication to advancing dental sleep medicine […]
As the prevalence of atrial fibrillation (AF) continues to rise, particularly among the aging population, its connection with obstructive sleep apnea (OSA) has become increasingly evident.1 Patients with AF seeking treatment for OSA often present with a complex medical history that includes a number of comorbidities, such as hypertension, acid […]
Aesyra, a medical device company pioneering oral appliance technologies to improve sleep, today announced it has raised $3 million in seed financing. The round was led by Supermoon Capital (USA), the world’s first fund focused on sleeptech, and deep tech investor Creadd Ventures (Switzerland) with participation from existing investor Zürcher […]
Vivos Therapeutics, Inc. announced it has been granted 510(k) clearance from the U.S. Food and Drug Administration (FDA) for treating severe obstructive sleep apnea (OSA) in adults using the Vivos’ removable CARE (Complete Airway Repositioning and/or Expansion) oral appliances. Vivos’ CARE appliances include the flagship DNA oral appliance, the mRNA […]
ProSomnus, Inc. has announced the completion of a $10 million convertible preferred equity offering led by existing investors Spring Mountain Capital and Cetus Capital, LLC. ProSomnus’s Executive Chair, Chief Executive Officer, and Chief Financial Officer are also participating in the financing. A description of the terms of the offering can […]
ProSomnus, Inc. announced plans to design a head-to-head clinical trial comparing its precision oral appliance therapy (OAT) and hypoglossal nerve stimulation (HGNS) in treating patients with severe OSA. The clinical trial plans follow updated results from the First Line Obstructive Sleep Apnea Treatment Study (FLOSAT), a prospective, independent, head-to-head, crossover […]
